Summary

Nasal Polyposis Treatment Market – Scope of Report
TMR’s report on the global nasal polyposis treatment market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2024 to 2034. The report provides revenue of the global nasal polyposis treatment market for the period 2018–2034, considering 2024 as the base year and 2034 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global nasal polyposis treatment market from 2024 to 2034.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the nasal polyposis treatment market.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global nasal polyposis treatment market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global nasal polyposis treatment market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global nasal polyposis treatment market.

The report delves into the competitive landscape of the global nasal polyposis treatment market. Key players operating in the global nasal polyposis treatment market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global nasal polyposis treatment market profiled in this report.

Key Questions Answered in Global nasal polyposis treatment Market Report
• What is the sales/revenue generated by nasal polyposis treatment across all regions during the forecast period?
• What are the opportunities in the global nasal polyposis treatment market?
• What are the major drivers, restraints, opportunities, and threats in the market?
• Which regional market is set to expand at the fastest CAGR during the forecast period?
• Which segment is expected to generate the highest revenue globally in 2034?
• Which segment is projected to expand at the highest CAGR during the forecast period?
• What are the market positions of different companies operating in the global market?

Nasal Polyposis Treatment Market – Research Objectives and Research Approach
The comprehensive report on the global nasal polyposis treatment market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global nasal polyposis treatment market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2034 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global nasal polyposis treatment market.

ページTOPに戻る

Table of Contents

1. Preface
    1.1. Market Definition and Scope
    1.2. Market Segmentation
    1.3. Key Research Objectives
    1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Nasal Polyposis Treatment Market
4. Market Overview
    4.1. Introduction
        4.1.1. Product Definition
        4.1.2. Industry Evolution/Developments
    4.2. Overview
    4.3. Market Dynamics
        4.3.1. Drivers
        4.3.2. Restraints
        4.3.3. Opportunities
    4.4. Nasal Polyposis Treatment Market Analysis and Forecast, 2020-2034
5. Key Insights
    5.1. Pipeline Analysis
    5.2. Key Product /Brand Analysis
    5.3. Key Mergers & Acquisitions
    5.4. COVID-19 Pandemic Impact on Industry
6. Global Nasal Polyposis Treatment Market Analysis and Forecast, by Drug Class
    6.1. Introduction & Definition
    6.2. Key Findings/Developments
    6.3. Market Value Forecast, by Drug Class, 2020-2034
        6.3.1. Corticosteroids
            6.3.1.1. Nasal Corticosteroids
                6.3.1.1.1. Fluticasone
                6.3.1.1.2. Budesonide
                6.3.1.1.3. Mometasone
                6.3.1.1.4. Triamcinolme
                6.3.1.1.5. Others (Beclomethasone, Ciclesonide, etc.)
            6.3.1.2. Oral/Injection Corticosteroids
                6.3.1.2.1. Prednisone
                6.3.1.2.2. Combination
        6.3.2. Monoclonal Antibodies
            6.3.2.1. Mepolizumab
            6.3.2.2. Omalizumab
        6.3.3. Antibiotics
        6.3.4. Antihistamines
        6.3.5. Others (Aspirin, Anti-Cholinergic Agent, etc.)
    6.4. Market Attractiveness Analysis, by Drug Class
7. Global Nasal Polyposis Treatment Market Analysis and Forecast, by Route of Administration
    7.1. Introduction & Definition
    7.2. Key Findings/Developments
    7.3. Market Value Forecast, by Route of Administration, 2020-2034
        7.3.1. Nasal
        7.3.2. Oral
        7.3.3. Parenteral
    7.4. Market Attractiveness Analysis, by Route of Administration
8. Global Nasal Polyposis Treatment Market Analysis and Forecast, by Distribution Channel
    8.1. Introduction & Definition
    8.2. Key Findings/Developments
    8.3. Market Value Forecast, by Distribution Channel, 2020-2034
        8.3.1. Hospital Pharmacies
        8.3.2. Retail Pharmacies
        8.3.3. Online Pharmacies
    8.4. Market Attractiveness Analysis, by Distribution Channel
9. Global Nasal Polyposis Treatment Market Analysis and Forecast, by Region
    9.1. Key Findings
    9.2. Market Value Forecast, by Region, 2020-2034
        9.2.1. North America
        9.2.2. Europe
        9.2.3. Asia Pacific
        9.2.4. Latin America
        9.2.5. Middle East & Africa
    9.3. Market Attractiveness Analysis, by Region
10. North America Nasal Polyposis Treatment Market Analysis and Forecast
    10.1. Introduction
    10.2. Key Findings
    10.3. Market Value Forecast, by Drug Class, 2020-2034
        10.3.1. Corticosteroids
            10.3.1.1. Nasal Corticosteroids
                10.3.1.1.1. Fluticasone
                10.3.1.1.2. Budesonide
                10.3.1.1.3. Mometasone
                10.3.1.1.4. Triamcinolme
                10.3.1.1.5. Others (Beclomethasone, Ciclesonide, etc.)
            10.3.1.2. Oral/Injection Corticosteroids
                10.3.1.2.1. Prednisone
                10.3.1.2.2. Combination
        10.3.2. Monoclonal Antibodies
            10.3.2.1. Mepolizumab
            10.3.2.2. Omalizumab
        10.3.3. Antibiotics
        10.3.4. Antihistamines
        10.3.5. Others (Aspirin, Anti-Cholinergic Agent, etc.)
    10.4. Market Value Forecast, by Route of Administration, 2020-2034
        10.4.1. Nasal
        10.4.2. Oral
        10.4.3. Parenteral
    10.5. Market Value Forecast, by Distribution Channel, 2020-2034
        10.5.1. Hospital Pharmacies
        10.5.2. Retail Pharmacies
        10.5.3. Online Pharmacies
    10.6. Market Value Forecast, by Country, 2020-2034
        10.6.1. U.S.
        10.6.2. Canada
    10.7. Market Attractiveness Analysis
        10.7.1. By Drug Class
        10.7.2. By Route of Administration
        10.7.3. By Distribution Channel
        10.7.4. By Country
11. Europe Nasal Polyposis Treatment Market Analysis and Forecast
    11.1. Introduction
    11.2. Key Findings
    11.3. Market Value Forecast, by Drug Class, 2020-2034
        11.3.1. Corticosteroids
            11.3.1.1. Nasal Corticosteroids
                11.3.1.1.1. Fluticasone
                11.3.1.1.2. Budesonide
                11.3.1.1.3. Mometasone
                11.3.1.1.4. Triamcinolme
                11.3.1.1.5. Others (Beclomethasone, Ciclesonide, etc.)
            11.3.1.2. Oral/Injection Corticosteroids
                11.3.1.2.1. Prednisone
                11.3.1.2.2. Combination
        11.3.2. Monoclonal Antibodies
            11.3.2.1. Mepolizumab
            11.3.2.2. Omalizumab
        11.3.3. Antibiotics
        11.3.4. Antihistamines
        11.3.5. Others (Aspirin, Anti-Cholinergic Agent, etc.)
    11.4. Market Value Forecast, by Route of Administration, 2020-2034
        11.4.1. Nasal
        11.4.2. Oral
        11.4.3. Parenteral
    11.5. Market Value Forecast, by Distribution Channel, 2020-2034
        11.5.1. Hospital Pharmacies
        11.5.2. Retail Pharmacies
        11.5.3. Online Pharmacies
    11.6. Market Value Forecast, by Country/Sub-region, 2020-2034
        11.6.1. Germany
        11.6.2. U.K.
        11.6.3. France
        11.6.4. Italy
        11.6.5. Spain
        11.6.6. Rest of Europe
    11.7. Market Attractiveness Analysis
        11.7.1. By Drug Class
        11.7.2. By Route of Administration
        11.7.3. By Distribution Channel
        11.7.4. By Country/Sub-region
12. Asia Pacific Nasal Polyposis Treatment Market Analysis and Forecast
    12.1. Introduction
    12.2. Key Findings
    12.3. Market Value Forecast, by Drug Class, 2020-2034
        12.3.1. Corticosteroids
            12.3.1.1. Nasal Corticosteroids
                12.3.1.1.1. Fluticasone
                12.3.1.1.2. Budesonide
                12.3.1.1.3. Mometasone
                12.3.1.1.4. Triamcinolme
                12.3.1.1.5. Others (Beclomethasone, Ciclesonide, etc.)
            12.3.1.2. Oral/Injection Corticosteroids
                12.3.1.2.1. Prednisone
                12.3.1.2.2. Combination
        12.3.2. Monoclonal Antibodies
            12.3.2.1. Mepolizumab
            12.3.2.2. Omalizumab
        12.3.3. Antibiotics
        12.3.4. Antihistamines
        12.3.5. Others (Aspirin, Anti-Cholinergic Agent, etc.)
    12.4. Market Value Forecast, by Route of Administration, 2020-2034
        12.4.1. Nasal
        12.4.2. Oral
        12.4.3. Parenteral
    12.5. Market Value Forecast, by Distribution Channel, 2020-2034
        12.5.1. Hospital Pharmacies
        12.5.2. Retail Pharmacies
        12.5.3. Online Pharmacies
    12.6. Market Value Forecast, by Country/Sub-region, 2020-2034
        12.6.1. China
        12.6.2. Japan
        12.6.3. India
        12.6.4. Australia & New Zealand
        12.6.5. Rest of Asia Pacific
    12.7. Market Attractiveness Analysis
        12.7.1. By Drug Class
        12.7.2. By Route of Administration
        12.7.3. By Distribution Channel
        12.7.4. By Country/Sub-region
13. Latin America Nasal Polyposis Treatment Market Analysis and Forecast
    13.1. Introduction
    13.2. Key Findings
    13.3. Market Value Forecast, by Drug Class, 2020-2034
        13.3.1. Corticosteroids
            13.3.1.1. Nasal Corticosteroids
                13.3.1.1.1. Fluticasone
                13.3.1.1.2. Budesonide
                13.3.1.1.3. Mometasone
                13.3.1.1.4. Triamcinolme
                13.3.1.1.5. Others (Beclomethasone, Ciclesonide, etc.)
            13.3.1.2. Oral/Injection Corticosteroids
                13.3.1.2.1. Prednisone
                13.3.1.2.2. Combination
        13.3.2. Monoclonal Antibodies
            13.3.2.1. Mepolizumab
            13.3.2.2. Omalizumab
        13.3.3. Antibiotics
        13.3.4. Antihistamines
        13.3.5. Others (Aspirin, Anti-Cholinergic Agent, etc.)
    13.4. Market Value Forecast, by Route of Administration, 2020-2034
        13.4.1. Nasal
        13.4.2. Oral
        13.4.3. Parenteral
    13.5. Market Value Forecast, by Distribution Channel, 2020-2034
        13.5.1. Hospital Pharmacies
        13.5.2. Retail Pharmacies
        13.5.3. Online Pharmacies
    13.6. Market Value Forecast, by Country/Sub-region, 2020-2034
        13.6.1. Brazil
        13.6.2. Mexico
        13.6.3. Rest of Latin America
    13.7. Market Attractiveness Analysis
        13.7.1. By Drug Class
        13.7.2. By Route of Administration
        13.7.3. By Distribution Channel
        13.7.4. By Country/Sub-region
14. Middle East & Africa Nasal Polyposis Treatment Market Analysis and Forecast
    14.1. Introduction
    14.2. Key Findings
    14.3. Market Value Forecast, by Drug Class, 2020-2034
        14.3.1. Corticosteroids
            14.3.1.1. Nasal Corticosteroids
                14.3.1.1.1. Fluticasone
                14.3.1.1.2. Budesonide
                14.3.1.1.3. Mometasone
                14.3.1.1.4. Triamcinolme
                14.3.1.1.5. Others (Beclomethasone, Ciclesonide, etc.)
            14.3.1.2. Oral/Injection Corticosteroids
                14.3.1.2.1. Prednisone
                14.3.1.2.2. Combination
        14.3.2. Monoclonal Antibodies
            14.3.2.1. Mepolizumab
            14.3.2.2. Omalizumab
        14.3.3. Antibiotics
        14.3.4. Antihistamines
        14.3.5. Others (Aspirin, Anti-Cholinergic Agent, etc.)
    14.4. Market Value Forecast, by Route of Administration, 2020-2034
        14.4.1. Nasal
        14.4.2. Oral
        14.4.3. Parenteral
    14.5. Market Value Forecast, by Distribution Channel, 2020-2034
        14.5.1. Hospital Pharmacies
        14.5.2. Retail Pharmacies
        14.5.3. Online Pharmacies
    14.6. Market Value Forecast, by Country/Sub-region, 2020-2034
        14.6.1. GCC Countries
        14.6.2. South Africa
        14.6.3. Rest of Middle East & Africa
    14.7. Market Attractiveness Analysis
        14.7.1. By Drug Class
        14.7.2. By Route of Administration
        14.7.3. By Distribution Channel
        14.7.4. By Country/Sub-region
15. Competition Landscape
    15.1. Market Player - Competitive Matrix (by Tier and Size of Companies)
    15.2. Market Share Analysis, by Company (2023)
    15.3. Company Profiles
        15.3.1. Abbott Laboratories
            15.3.1.1. Company Overview
            15.3.1.2. Product Portfolio
            15.3.1.3. SWOT Analysis
            15.3.1.4. Financial Overview
            15.3.1.5. Strategic Overview
        15.3.2. Sanofi S.A.
            15.3.2.1. Company Overview
            15.3.2.2. Product Portfolio
            15.3.2.3. SWOT Analysis
            15.3.2.4. Financial Overview
            15.3.2.5. Strategic Overview
        15.3.3. AstraZeneca
            15.3.3.1. Company Overview
            15.3.3.2. Product Portfolio
            15.3.3.3. SWOT Analysis
            15.3.3.4. Financial Overview
            15.3.3.5. Strategic Overview
        15.3.4. Teva Pharmaceutical Industries Ltd.
            15.3.4.1. Company Overview
            15.3.4.2. Product Portfolio
            15.3.4.3. SWOT Analysis
            15.3.4.4. Financial Overview
            15.3.4.5. Strategic Overview
        15.3.5. Johnson & Johnson Services, Inc.
            15.3.5.1. Company Overview
            15.3.5.2. Product Portfolio
            15.3.5.3. SWOT Analysis
            15.3.5.4. Financial Overview
            15.3.5.5. Strategic Overview
        15.3.6. Pfizer Inc.
            15.3.6.1. Company Overview
            15.3.6.2. Product Portfolio
            15.3.6.3. SWOT Analysis
            15.3.6.4. Financial Overview
            15.3.6.5. Strategic Overview
        15.3.7. Novartis AG
            15.3.7.1. Company Overview
            15.3.7.2. Product Portfolio
            15.3.7.3. SWOT Analysis
            15.3.7.4. Financial Overview
            15.3.7.5. Strategic Overview
        15.3.8. GSK plc
            15.3.8.1. Company Overview
            15.3.8.2. Product Portfolio
            15.3.8.3. SWOT Analysis
            15.3.8.4. Financial Overview
            15.3.8.5. Strategic Overview
        15.3.9. Bayer AG
            15.3.9.1. Company Overview
            15.3.9.2. Product Portfolio
            15.3.9.3. SWOT Analysis
            15.3.9.4. Financial Overview
            15.3.9.5. Strategic Overview
        15.3.10. Sun Pharmaceutical Industries Ltd.
            15.3.10.1. Company Overview
            15.3.10.2. Product Portfolio
            15.3.10.3. SWOT Analysis
            15.3.10.4. Financial Overview
            15.3.10.5. Strategic Overview
        15.3.11. Cipla Ltd.
            15.3.11.1. Company Overview
            15.3.11.2. Product Portfolio
            15.3.11.3. SWOT Analysis
            15.3.11.4. Financial Overview
            15.3.11.5. Strategic Overview
        15.3.12. Mylan N.V.
            15.3.12.1. Company Overview
            15.3.12.2. Product Portfolio
            15.3.12.3. SWOT Analysis
            15.3.12.4. Financial Overview
            15.3.12.5. Strategic Overview
        15.3.13. Merck KGaA
            15.3.13.1. Company Overview
            15.3.13.2. Product Portfolio
            15.3.13.3. SWOT Analysis
            15.3.13.4. Financial Overview
            15.3.13.5. Strategic Overview